Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

BACKGROUND: Coronavirus disease 2019 (Covid-19) pneumonia is often associated with hyperinflammation. Despite the disproportionate incidence of Covid-19 among underserved and racial and ethnic minority populations, the safety and efficacy of the anti–interleukin-6 receptor antibody tocilizumab in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Salama, Carlos, Han, Jian, Yau, Linda, Reiss, William G., Kramer, Benjamin, Neidhart, Jeffrey D., Criner, Gerard J., Kaplan-Lewis, Emma, Baden, Rachel, Pandit, Lavannya, Cameron, Miriam L., Garcia-Diaz, Julia, Chávez, Victoria, Mekebeb-Reuter, Martha, Lima de Menezes, Ferdinando, Shah, Reena, González-Lara, Maria F., Assman, Beverly, Freedman, Jamie, Mohan, Shalini V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781101/
https://www.ncbi.nlm.nih.gov/pubmed/33332779
http://dx.doi.org/10.1056/NEJMoa2030340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781101/
https://www.ncbi.nlm.nih.gov/pubmed/33332779
http://dx.doi.org/10.1056/NEJMoa2030340

Ejemplares similares